NetworkNewsBreaks

ThursdayFeb 27, 2020 2:22 pm

NetworkNewsBreaks – Lonestar Resources US Inc. (NASDAQ: LONE) Featured in ROTH Equity Research Report

Lonestar Resources US Inc. (NASDAQ: LONE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “LONE recently announced an Eagle Ford Shale joint development agreement. The JDA allows for the two companies to consolidate their acreage positions into a single development plan which should: 1) maximize lateral lengths, 2) optimize economic returns, and 3) efficiently HBP the combined leasehold with the fewest number of wells. Further, the JDA will allow LONE to increase its inventory of gross drilling locations by roughly 50% in the Hawkeye area to a total of 32 while…

Continue Reading

ThursdayFeb 27, 2020 2:10 pm

NetworkNewsBreaks – Paramount Gold Nevada Corp. (NYSE American: PZG) Featured in ROTH Equity Research Report

Paramount Gold Nevada Corp. (NYSE American: PZG) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “On February 26, 2020, Paramount Gold Nevada announced the submission of its Plan of Operation for its Grassy Mountain gold project. We view the Plan of Operation submission to the Bureau of Land Management (BLM) as a major step forward in the permitting process at Grassy Mountain as the federal permitting process can now begin. As such, we are reiterating a Buy rating and $4.00 price target.” To request access to the full report, visit http://nnw.fm/DXCr3…

Continue Reading

ThursdayFeb 27, 2020 2:03 pm

NetworkNewsBreaks – NV5 Global, Inc. (NASDAQ: NVEE) Featured in ROTH Equity Research Report

NV5 Global, Inc. (NASDAQ: NVEE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We maintain our conviction that 2020 will prove to be a year of healthy organic growth, with an improved margin profile. We believe the core business remains strong, particularly within the Energy group. The acquisition of QSI enhances both the growth and margin profile of the business; results from December and into January and February for QSI are encouraging. We reiterate our Buy rating and $91 price target, noting NVEE is a top pick for 2020.” To request…

Continue Reading

ThursdayFeb 27, 2020 1:54 pm

NetworkNewsBreaks – RedHill Biopharma Ltd. (NASDAQ: RDHL) Featured in ROTH Equity Research Report

RedHill Biopharma Ltd. (NASDAQ: RDHL) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We publish our updated RDHL model post the acquisition of Movantik. Key takeaways, in our opinion, include: 1) we expect continuation of modest prescription declines for Movantik, 2) we target minimal initial revenues for Aemcolo, 3) Talicia remains the wildcard with the most variability (we are optimistic), and 4) we target breakeven in 2021. Reiterate Buy rating with price target adjusted to $15/share.” To request access to the full report, visit http://nnw.fm/DXCr3 About RedHill Biopharma Ltd. RedHill Biopharma…

Continue Reading

ThursdayFeb 27, 2020 1:47 pm

NetworkNewsBreaks – Bicycle Therapeutics, PLC (NASDAQ: BCYC) Featured in ROTH Equity Research Report

Bicycle Therapeutics, PLC (NASDAQ: BCYC) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “Bicycle today announced a new strategic collaboration agreement with Genentech to discover, develop, and commercialize novel Bicycle-based immuno-oncology (IO) therapies. Bicycle will receive a $30 million upfront payment as part of this early discovery collaboration with the possibility to receive a total of $1.7 billion in aggregate payments based on discovery, development, regulatory, and commercial milestones. See the full report for details.” To request access to the full report, visit http://nnw.fm/DXCr3 About Bicycle Therapeutics, PLC Bicycle Therapeutics is…

Continue Reading

ThursdayFeb 27, 2020 1:41 pm

NetworkNewsBreaks – Acer Therapeutics, Inc. (NASDAQ: ACER) Featured in ROTH Equity Research Report

Acer Therapeutics, Inc. (NASDAQ: ACER) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “With yesterday's update that ACER-001 showed bioequivalence to the already approved Buphenyl for treatment of UCDs, ACER now has green lights ahead of a planned NDA submission for its taste-masked drug in early 2021. With NDA-bound ACER-001 development on the upswing and the FDRR for EDSIVO in review (submitted Dec. 2019), we believe the follow-through on execution has set ACER up for a strong 2020.” To request access to the full report, visit http://nnw.fm/DXCr3 About Acer Therapeutics, Inc.…

Continue Reading

ThursdayFeb 27, 2020 1:25 pm

NetworkNewsBreaks – Ampio Pharmaceuticals Inc. (NYSE American: AMPE) Featured in ROTH Equity Research Report

Ampio Pharmaceuticals Inc. (NYSE American: AMPE) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “AMPE continues to swiftly enroll patients into its AP-013 confirmatory Phase 3 trial in severe osteoarthritis of the knee (OAK KL4), which is determining the clinical effect of Ampion on pain and function at 12 weeks in this debilitating indication. As of February 14, 875 patients were enrolled out of a minimum required 1,034, and more than 600 patients have reached the trial's 12-week primary endpoint (>58% completed), setting up for data release in 3Q20.” To request…

Continue Reading

ThursdayFeb 27, 2020 1:12 pm

NetworkNewsBreaks – Ayr Strategies, Inc. (CSE: AYR.A) (OTCQX: AYRSF) Featured in ROTH Equity Research Report

Ayr Strategies, Inc. (CSE: AYR.A) (OTCQX: AYRSF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “AYR reports 4Q19 quarterly results before the market open on February 27, 2020, where we expect results mostly in-line with consensus, while continuing to demonstrate positive AEBITDA. We are more confident with 2020 estimates tied to MA removing the vape ban in mid December and the approval of the company's second cultivation license to expand its MA wholesale segment. We had anticipated a three-month delay on licensing, but earlier approval now supports 2020 guidance. We maintain…

Continue Reading

ThursdayFeb 27, 2020 1:07 pm

NetworkNewsBreaks – WeedMD Inc.’s (TSX.V: WMD) (OTCQX: WDDMF) (FSE: 4WE) Starseed is Preferred Medical Cannabis Supplier to Insulators Local 95 Health & Welfare Trust Fund

WeedMD (TSX-V: WMD) (OTCQX: WDDMF) (FSE: 4WE), a federally-licensed producer and distributor of medical-grade cannabis, on Wednesday announced that its subsidiary, Starseed Medicinal Inc., is now the preferred medical cannabis supplier to the Insulators Local 95 Health & Welfare Trust Fund. According to the update, the agreement provides union members and their dependents access to medical cannabis as an insured benefit with no out-of-pocket costs or co-pays. “Starseed’s unique and proprietary program is rapidly becoming the platform of choice for benefits providers, insurers and their members looking to seamlessly add medical cannabis in a responsible way,” WeedMD CEO Angelo Tsebelis…

Continue Reading

ThursdayFeb 27, 2020 12:59 pm

NetworkNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) to Effect Reverse Stock Split to Regain Compliance with Nasdaq Listing Rule

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it will effect a one-for-ten reverse stock split of its outstanding common stock to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2). According to the update, Sigma’s common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis at market open on Friday, February 28, 2020, and will continue to trade under the “SGLB” symbol. Following the reverse stock split, the new CUSIP number for the common stock…

Continue Reading